Oral anticoagulation (OAC) reduces thromboembolic events associated with atrial fibrillation (AF), yet 50% of AF patient are not prescribed OAC. Recent studies, including our preliminary findings, also showed significant racial disparity in OAC prescription even after accounting for access to care, health insurance and stroke risk factors. In this study, we will evaluate whether amount of drug cost-sharing, supplemental coverage and OAC contraindications explain OAC underuse and racial disparity in prescription of OAC in AF patients.
|Effective start/end date||3/23/20 → 3/23/23|
- Bristol-Myers Squibb Company (Agmt 3/23/20)